Publication: Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Loading...
Identifiers
Date
2022-07-12
Authors
Bastos-Oreiro, Mariana
Gutierrez, Antonio
Reguera, Juan Luís
Iacoboni, Gloria
López-Corral, Lucía
Terol, María José
Ortíz-Maldonado, Valentín
Sanz, Jaime
Guerra-Dominguez, Luisa
Bailen, Rebeca
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 months, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 months, p
Description
MeSH Terms
Antigens, CD19
Humans
Lymphoma, Large B-Cell, Diffuse
Receptors, Chimeric Antigen
Retrospective Studies
T-Lymphocytes
Humans
Lymphoma, Large B-Cell, Diffuse
Receptors, Chimeric Antigen
Retrospective Studies
T-Lymphocytes
DeCS Terms
CIE Terms
Keywords
CAR-T cell therapy, real world evidence (RWE), refractory aggressive B cell lymphoma, scholar-1 criteria, standard of care (SOC)